Boehringer Ingelheim Animal Health celebrates 20 years of PRRS control and innovation

Views tracker viewed for user 71271
Boehringer Ingelheim's picture
Printer-friendly versionPrinter-friendly version

• PRRS: Porcine Reproductive and Respiratory Syndrome
• PRRS infects pigs around the globe with devastating consequences
• Boehringer Ingelheim Animal Health will continue intensive research and development in the field of PRRS

Ingelheim, Germany, 22 August 2014 – Twenty years ago Boehringer Ingelheim Animal Health launched Ingelvac® PRRS MLV, the first Modified Live Vaccine (MLV) for the management of Porcine Reproductive and Respiratory Syndrome (PRRS). PRRS infects pigs around the globe causing reproductive failure in breeding stock and respiratory tract illness in growing pigs. As a result, pigs suffer and die – causing economic damage to swine farmers worldwide.

Costs and losses due to PRRS were a major concern to swine farmers when Boehringer Ingelheim Animal Health launched Ingelvac® PRRS MLV vaccine in 1994. The vaccine was first introduced to US veterinarians in August of that year and soon was being made available internationally.

The vaccine’s two decades of outstanding success in combating PRRS is only one part of the anniversary in 2014. Boehringer Ingelheim Animal Health is also celebrating 20 years of highly productive collaborations with swine farmers, veterinarians and researchers around the world to manage this major pig disease.

George Heidgerken, Senior Vice President of Animal Health at Boehringer Ingelheim

"The journey over the last 20 years has given us the opportunity to work on consolidating our knowledge about PRRS as well as maximizing the use of our vaccine as one of the key tools for controlling the disease," states George Heidgerken, Senior Vice President of Animal Health at Boehringer Ingelheim. "We are proud of the fact that in the 20 years since we launched Ingelvac® PRRS MLV vaccine, we have been instrumental in funding and supporting research into the PRRS virus and limiting its effects in pigs. Out of this sustained work the global pig industry has gained practical and reliable ways of managing the threat of PRRS at farm level."

Supported by the results of international research regarding virus persistence and disease transmission, Boehringer Ingelheim Animal Health also strives to find solutions beyond the vaccine bottle through the creation of a systematic process for PRRS control. In the future, the company will continue to work with its customers in the pig industry in an effort to find ways to overcome the virus in all its forms.

Today, Ingelvac® PRRS MLV is the global market leader in the segment of PRRS vaccines.1 The vaccine has a strong worldwide presence, from North America to Europe and Asia.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.

News Source : Boehringer Ingelheim Animal Health celebrates 20 years of PRRS control and innovation
Copy this html code to your website/blog to embed this press release.

Boehringer Ingelheim Press Release

Post date
04/08/2016 - 05:38 The Lancet Respiratory Medicine: New analysis shows only minority of COPD patients may benefit from inhaled corticosteroids
04/07/2016 - 08:34 Giotrif (afatinib) approved in Europe as new oral treatment option for patients with squamous cell carcinoma of the lung
04/04/2016 - 07:00 Interim Phase III Data Show Praxbind (idarucizumab) Reverses Dabigatran (Pradaxa) in Emergency Situations
03/30/2016 - 06:18 Boehringer Ingelheim Venture Fund invests in Amal Therapeutics to develop novel therapeutic colorectal cancer vaccine
03/23/2016 - 13:39 Boehringer Ingelheim launches RE-COVERY DVT/PE: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa (dabigatran etexilate)
03/15/2016 - 08:04 2016 European PRRS Research Award: Boehringer Ingelheim Animal Health calls for submissions until
03/08/2016 - 09:58 New Analyses: Adding SPIRIVA Respimat Effective for Uncontrolled Asthma Regardless of Allergy Subtype 1,2,3
03/07/2016 - 09:38 AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds
03/01/2016 - 05:41 Boehringer Ingelheim Animal Health supports independent PCV2 research with total of 650,000
02/29/2016 - 10:12 European Committee for Medicinal Products for Human Use recommends approval of Giotrif (afatinib) for advanced squamous cell cancer of the lung
02/29/2016 - 06:08 New survey gives voice to people living with a rare and devastating lung disease: When I think of IPF I think of breathlessness
02/25/2016 - 06:10 New analysis confirms OFEV (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
02/10/2016 - 12:57 The European Society of Cardiology announces winners of innovative cardiovascular research grant programme
02/04/2016 - 12:20 SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
01/15/2016 - 12:04 World Association for Buiatrics and Boehringer Ingelheim Animal Health announce “Ruminant Well-being Award”
01/13/2016 - 16:21 Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to Advance Research in Schizophrenia
12/22/2015 - 08:07 Boehringer Ingelheim Invests in Europe: Pharma Company Expands Biopharmaceutical Production at Vienna Site
12/21/2015 - 08:29 Boehringer Ingelheim 3 rd -generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer
12/18/2015 - 10:12 Boehringer Ingelheim presents strong lung cancer portfolio and long-awaited head-to-head data of afatinib compared to gefitinib at ESMO Asia 2015 Congress
12/15/2015 - 12:58 Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap
Copy and paste this code to display this page on your website .
Syndicate content